FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
Uncover the truth about ‘preventative’ chemotherapy with insights on its actual use. Learn about real preventive measures that can effectively reduce cancer risk and protect…
Published online: May 01, 2024 Request permissions for this article. Health Sciences North Research Institute, Northern Ontario School of Medicine, Health Sciences North, Sudbury, Ontario,…
Dr. Narjust Florez, Lung Cancer Considered Host, encourages members to participate in the first IASLC Global Membership Survey on Inclusivity. The 5-minute survey, is available…
Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has…
The panelists explore the importance of communicating with patients, nurses, and caregivers about potential adverse reactions and injection site reactions, while emphasizing the need to…
The annual Champions for Change Gala is The Skin Cancer Foundation’s signature fundraising event. Funds raised from the Gala support the Foundation’s lifesaving educational campaigns,…
Dr. Kuykendall discusses the efficacy and safety findings from studies like MAJIC-PV and PROUD-PV, and how they influence his treatment choices for PV.
Exposure to propofol was associated with an increased risk of impairment in reaction time/processing speed at 1 year after treatment in children with high-risk B-cell…
Sharon Dent, Ph.D., professor of Epigenetics and Molecular Carcinogenesis, and dean of the Graduate School of Biomedical Sciences at The University of Texas MD Anderson…
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who…